News

Roche: RoActemra beats Humira
Enlarge image

BusinessSwitzerland

Roche: RoActemra beats Humira

08.06.2012 - Roche's rheumatoid arthritis treatment RoActemra reduces symptoms more effectively than Abbott Laboratories' Humira when given as a single treatment.

Basel – As the Swiss company reported, a Phase IV trial showed that after 24 weeks of treatment 65% of patients who received RoActemra (tocilizumab) experienced a 20% reduction in swollen and tender joints compared with 49% of those on Humira (adalimumab). „As there are a number of therapies approved for patients with rheumatoid arthritis, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option,“ said Hal Barron, Chief Medical Officer and Head, Global Product Development. While Roche strongly advocates for its RoActemra, Analysts seem to be less convinced: „Despite these strong efficacy results, it is difficult to assess whether these trial results can be successfully exploited to bring about a change in physicians' prescription habits,“ said Vontobel analyst Andrew Weiss.

„Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician“, acknowledged Karsten Jung, Head of GPS Immunology at Roche, adding that the study aimed at giving comparative data to doctors to help them to decidea in favor of RoActemra when prescribing a treatment.

FDA and EMA have approved RoActemra for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation. Roche earned CHF184m in the first quarter 2012 (+46%). Analysts expect peak sales of up to US$2b for the drug. Rheumatoid arthritis and related diseases are one of the most lucrative areas for pharma companies, generating more than US$20b in annual sales. Humira sales are expected to reach US$8.7bn in 2012, according to an EvaluatePharma report.

http://www.european-biotechnology-news.com/news/news/2012-02/roche-roactemra-beats-humira.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%

FLOP

  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%

TOP

  • SYNGENTA430.80 CHF32.0%
  • EVOLVA1.84 CHF20.3%
  • BASILEA132.00 CHF16.7%

FLOP

  • CYTOS0.66 CHF-32.7%
  • MEDIGENE8.43 EUR-19.3%
  • 4SC4.65 EUR-10.6%

TOP

  • WILEX3.95 EUR393.7%
  • FORMYCON28.39 EUR318.7%
  • 4SC4.65 EUR307.9%

FLOP

  • MOLOGEN5.05 EUR-52.5%
  • PAION2.54 EUR-26.8%
  • BIOFRONTERA2.29 EUR-25.6%

No liability assumed, Date: 28.05.2015